Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ZYME

Zymeworks Inc.

Pharmaceutical Preparations · SIC 2834CIK 1937653Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$106.0M
Net Income FY2025
$(81.0M)
EPS (Basic, as reported)
$-1.08
Net Margin FY2025
-76.6%
ROE FY2025
-30.2%
Total Equity
$269.0M
Shares Out
71M
Business description

Zymeworks Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 39 → 106 +22.1% CAGR
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue39274127676106
Research & development(171)(200)(209)(144)——
General & administrative(55)(43)(73)(70)(62)(62)
Total operating expenses(226)(242)(282)(214)(213)(199)
Operating income(187)(216)131(138)(137)(93)
Other income (expense), net211(1)1(1)
Pre-tax income(180)(212)135(119)(117)(80)
Income tax expense0(1)(11)(1)(6)(1)
Net income(181)(212)124(119)(123)(81)
EPS — basic($3.58)($4.11)$1.91($1.72)($1.62)($1.08)
EPS — diluted($3.58)($4.61)$1.90($1.72)($1.62)($1.08)
Shares outstanding — basic (M)505265697675
Shares outstanding — diluted (M)505265697675

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.